Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study supplemental material

Name: Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study supplemental material
Creator: Kurt Gebauer
Published: 2024-03-25T05:09:33.630Z
Keywords: Dermatology, Psoriasis

Gebauer, Kurt; Spelman, Lynda; Yamauchi, Paul; Bagel, Jerry; Nishandar, Tushar; Crane, Michael; Kopeloff, Iris; Kothekar, Mudgal; Yao, Siu-Long; Sofen, Howard

doi:10.17632/zh7bx2my7f.1

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study supplemental material

Published: 25 March 2024| Version 1 | DOI: 10.17632/zh7bx2my7f.1

Contributors:

Kurt Gebauer, Lynda Spelman, Paul Yamauchi, Jerry Bagel, Tushar Nishandar, Michael Crane, Iris Kopeloff, Mudgal Kothekar, Siu-Long Yao, Howard Sofen

Description

This is the supplemental material for the manuscript titled, "Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study" by Gebauer K. et al., 2024.

Files

Funding

Sun Pharma

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study supplemental material

Description

Files

Categories

Funding

Licence